Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Sep 16, 2019 1:11pm
87 Views
Post# 30131853

RE:RE:RE:RE:RE:Prediction ???

RE:RE:RE:RE:RE:Prediction ???Regardless what is happining with opiods and those companies that sold ithem in agressive ways, GUD  is not exposed to opiods thus no risk to us shareholders period. Furhter telling shareholders to sell after five Years being invested in GUD is insulting at best. We have a right to complain fiercley becasue some of us know too damn well what JG said and or implied to share olders in news releases in the last five Years back. At this pace it may take 100 Years.  " GUD will have more pharma licences in Canda than what Phizer has" The bigest Material news so far that GUD has made has been in the form of Meir becoming an activist and mud slingng. Sure hell GUD MNGT should and could have done a lot better than that as good deals are being made evryday and wee by other biotech. Now we get complete long silence unless Meir teras again and we get JG confidence that he knows best and if you do not like sell. We Will see at the next AGM given that GUD MNGT will not take questions from share holders  other than lame duck incompetent analyst. yes I am not happy and I sell when and if  I want and no one should tell shareholders like me that if I do not like I should sell. Most of us including rock have a right to object and complain and hold JG to his promises by asking him questions. 
Bullboard Posts